PM-477
First-in-class synthetic lysin
Medical need:
Bacterial vaginosis
High efficacy,
high precision
Pathogen:
Gardnerella spp.
Patient population:
1 in 4 women (aged 15-49) p.a. globally
Recurrence:
60% within 6 months
Current standard-of-care:
Broad-spectrum antibiotics (acute) and long-term suppressive antibiotics (chronic)
Cleaving domain
PM-477 has a cleaving domain. After it binds to the cell wall, it lyses it. The cell bursts and the bacteria die.
Binding domain
PM-477 has a Gardnerella specific binding domain. It only binds to the cell wall of Gardnerella bacteria. It is specific.
Discovery
Lead optimization
Pre-clinical
Phase I
Phase II
Read our Publication in Pathogens
The first publication detailing PM-477 is now available.
Scientific Advisory Board
